GRADE for reducing adverse outcomes actions to reduce adverse outcomes should be based on confidence in estimates of effectactions to reduce adverse outcomes.

Slides:



Advertisements
Similar presentations
Progress in Vascular Anesthesiology Donald M. Voltz, M.D. Assistant Professor of Anesthesiology Case Western Reserve University/University Hospitals of.
Advertisements

Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.
University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.
Rattan Juneja MD¹; Michael E. Stuart, MD 2,3 ; Sheri A. Strite 3 Indiana University School of Medicine, Indianapolis, Indiana¹ University of Washington,
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Sugar control in Critical care unit Senior clinical pharmacist : Lihua Fang Koo Foundation Cancer Center.
Clinical Outcomes with Newer Antihyperglycemic Agents
The Patient Undergoing Surgery: Proven Steps to Better Outcomes Ariel U. Spencer, MD Lafayette Surgical Clinic Lafayette, Indiana.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Insulin Therapy in the ICU:
Improving Patient Outcomes GLYCEMIC CONTROL IN PERI-OPERATIVE PATIENTS UTILIZING INSULIN INFUSION PROTOCOLS.
Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.
How to Analyze Therapy in the Medical Literature (part 2)
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Plan GRADE backgroundGRADE background confidence in estimates (quality of evidence)confidence in estimates (quality of evidence) evidence profilesevidence.
EVALUATION OF CONVENTIONAL V. INTENSIVE BLOOD GLUCOSE CONTROL Glycemic Control in Critically Ill Patients DANELLE BLUME UNIVERSITY OF GEORGIA COLLEGE OF.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit The SAFE Study Investigators N Engl J Med 2004: 350:
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Postoperative Glucose Control and SCIP Measures Gorav Ailawadi, MD Chief, Adult Cardiac Surgery University of Virginia April 25, 2015.
Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Daniel I. Sessler Department of O UTCOMES R ESEARCH Cleveland Clinic on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)
Relative Risk Therapy A Better Therapy B Better COMPASS 95% CI no worse than 1.5 TARGET 95% CI no worse than 1.47 ASSENT-2.
4S: Scandinavian Simvastatin Survival Study
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Discontinuation of medication after nonfatal event: MI
Clinical Outcomes with Newer Antihyperglycemic Agents
Why this talk? you will be seeing a lot of GRADE
ACCORD Design and Baseline Characteristics
The Importance of Adequately Powered Studies
Blood Pressure and Age in Controlling Hypertension
Conflicts of interest Major role in development of GRADE
LEADER trial: Primary Outcome
Alcohol, Other Drugs, and Health: Current Evidence
HOPE: Heart Outcomes Prevention Evaluation study
AIM HIGH Niacin plus Statin to prevent vascular events
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
Dabigatran in myocardial injury after noncardiac surgery
PROPPR Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. 
The Hypertension in the Very Elderly Trial (HYVET)
Plan GRADE background two steps evidence profiles
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Clonidine in Patients Having Noncardiac Surgery
Berger JS, et al. JAMA 2009;301:
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Systematic Reviews and Meta-Analysis -Part 2-
Presentation transcript:

GRADE for reducing adverse outcomes actions to reduce adverse outcomes should be based on confidence in estimates of effectactions to reduce adverse outcomes should be based on confidence in estimates of effect GRADE provides detailed guidance for assessing confidenceGRADE provides detailed guidance for assessing confidence avoids premature quality control initiativesavoids premature quality control initiatives

Confidence assessment criteria

TRIUMPH: Best Practices in Inpatient Glucose Monitoring UCLA Clinicians Use IT to Facilitate Innovations in Hyperglycemia Care

Hyperglycemia in the ICU A landmark clinical trial performed in 2001 changed clinicians' views about stress hyperglycemia in the inpatient setting. The authors of that New England Journal of Medicine study, concluded that "Intensive insulin therapy to maintain blood glucose at or below 110 mg per deciliter reduces morbidity and mortality among critically ill patients in the surgical intensive care unit" (Van Den Berghe, et al., 2001). A landmark clinical trial performed in 2001 changed clinicians' views about stress hyperglycemia in the inpatient setting. The authors of that New England Journal of Medicine study, concluded that "Intensive insulin therapy to maintain blood glucose at or below 110 mg per deciliter reduces morbidity and mortality among critically ill patients in the surgical intensive care unit" (Van Den Berghe, et al., 2001).

Van den Berghe, NEJM, patients surgical ICU, ventilated1548 patients surgical ICU, ventilated –intensive insulin therapy vs conventional planned to enroll 2,500planned to enroll 2,500 interim analysis at three month intervalsinterim analysis at three month intervals p < 0.01 (“designed to allow early stopping”)p < 0.01 (“designed to allow early stopping”) stopped after 4 th interim analysisstopped after 4 th interim analysis –98 deaths

Van den Berghe, NEJM, 2001 ICU mortalityICU mortality – –35 of 744 (4.6%) in intensive insulin – –63 of 765 (8.0%) in conventional RR 0.58 (95% CI 0.38 to 0.78)

GRADE assessment risk of biasrisk of bias –unblinded –conducted by enthusiasts –no documentation of co-intervention –stopped early precisionprecision –confidence intervals look OK but... –GRADE notes big effects often spurious analogy to stopping earlyanalogy to stopping early prognostic imbalanceprognostic imbalance –Optimal Information Size

Imprecision optimal information sizeoptimal information size –# of pts from conventional sample size calculation –specify control group risk, α, β, Δ 8% mortality, α 0.05, β 0.10, Δ RR 0.758% mortality, α 0.05, β 0.10, Δ RR ,838 vs 1,5486,838 vs 1,548 OIS not achievedOIS not achieved

Inconsistency/indirectness/ publication bias inconsistencyinconsistency –no problem indirectnessindirectness –single centre enthusiasts –will this be replicable? publication biaspublication bias –undetected

Confidence in 42% mortality  no confidence totally confident High Moderate Low Very Low risk of bias: no blinding, co-intervention, stopped early imprecision: well below optimal information size indirectness: single center of enthusiasts 27 trials in 13,572 patients : RR 0.93, 95% CI 0.83 – 1.04

Poldermans, NEJM, patients (planned sample size 266) –elective vascular surgery –positive dobutamine stress echo compared bisoprolol to placebo –unblinded primary endpoint death or nonfatal MI prior planned single look at 100 pts –stop if exceeded O’Brien-Fleming boundary p < 0.001

Poldermans NEJM 1999 primary endpoint –2 of 59 (3.4%) in bisoprolol group –18 of 53 (34%) in placebo RR 0.09, 95% CI 0.02 to 0.37, P< 0.001

Composite – Fixed Effects

GRADE assessment risk of bias –unblinded –no documentation of co-intervention –stopped early precision –confidence intervals look OK but... –total sample size 447 –Optimal Information Size 12% events, α 0.05, β 0.10, Δ RR 0.75 OIS 4,386

Inconsistency/indirectness/ publication bias inconsistency –I 2 50% indirectness –only positive trial odd population publication bias –undetected

Confidence in 60% mortality  no confidence totally confident High Moderate Low Very Low risk of bias: only positive study no blinding, co-intervention, stopped early imprecision: well below optimal information size indirectness: single center of enthusiasts inconsistency: I 2 50%

Quality Assessment Summary of Findings Quality Relative Effect (95% CI) Absolute risk difference Outcome Number of participants (studies) Risk of Bias ConsistencyDirectnessPrecision Publication Bias Myocardial infarction 10,125 (9) No serious limitations No serious imitations No serious limitations Not detected High 0.71 (0.57 to 0.86) 1.5% fewer (0.7% fewer to 2.1% fewer) Mortality 10,205 (7) No serious limitations Possiblly inconsistent No serious limitations Imprecise Not detected Moderate or low 1.23 (0.98 – 1.55) 0.5% more (0.1% fewer to 1.3% more) Stroke 10,889 (5) No serious limitaions No serious limitations Not detected High 2.21 (1.37 – 3.55) 0.5% more (0.2% more to 1.3% more0 Beta blockers in non-cardiac surgery

Conclusions reducing adverse outcomes requires accurate confidence in estimatesreducing adverse outcomes requires accurate confidence in estimates GRADE provides rigorous, transparent system assessing confidenceGRADE provides rigorous, transparent system assessing confidence